Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Comorbid Depressive and Anxiety Disorders

Nisha Ravindran, MD^a,b ; Martha McKay, PhD^c ; Angela Paric, PhD^a,b ; Sunny Johnson, MD^d ; Ranjith Chandrasena, MD^e ; Gaby Abraham, MD^a ; Arun V. Ravindran, MD, PhD^a,b

J Clin Psychiatry 2022;83(3):21m14096

ABSTRACT

Objective: Quetiapine is approved as an adjunctive treatment for major depressive disorder (MDD) and as monotherapy for bipolar depression. It is often used off-label for treating anxiety conditions and as an augmentation agent for treatment-resistant depression. However, its benefit in depression with comorbid anxiety disorders has not been systematically evaluated. The current study evaluated the benefit and tolerability of quetiapine as augmentation to first-line antidepressants for MDD comorbid with anxiety disorders.

Methods: In this multicenter trial (June 2008–June 2013), 76 adults (aged 18–65 years) with a primary diagnosis of unipolar depression comorbid with at least 1 anxiety disorder (per DSM-IV-TR criteria) received flexible-dose quetiapine extended-release (XR) 50–300 mg/d or placebo as add-on for 12 weeks in a 2:1 ratio. Depression, anxiety, life satisfaction, and adverse events were assessed.

Results: Depression, anxiety, and function improved significantly in both groups. On primary outcome measures, quetiapine was superior to placebo in improving depression (17-item Hamilton Depression Rating Scale score: mean difference = −3.64; 95% CI, −7.01 to –0.27) and anxiety symptoms (Hamilton Anxiety Rating Scale score: mean difference = –4.02; 95% CI, −7.41 to –0.64), as well as Clinical Global Impressions–Severity of Illness scale score (mean difference = –0.64; 95% CI, −1.13 to –0.15). On secondary measures including the Montgomery-Asberg Depression Rating Scale, Beck Depression Inventory, Penn State Worry Questionnaire, and Quality of Life Satisfaction and Enjoyment Questionnaire, quetiapine produced a greater degree of improvement compared to placebo, but group differences were not statistically significant. Quetiapine was well tolerated, with mostly minor and no serious adverse effects.

Conclusions: Quetiapine augmentation may be a useful intervention for MDD with comorbid anxiety.

Trial Registration: ClinicalTrials.gov Identifier: NCT00688818

Continue Reading...

Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (52)

Mathers CBT, Ma Fat D. The Global Burden of Disease: 2004 Update. WHO website. https://apps.who.int/iris/bitstream/handle/10665/43942/9789241563710_eng.pdf. 2008.
Whiteford HAP, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–1586. PubMed CrossRef
Remes O, Brayne C, van der Linde R, et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016;6(7):e00497. PubMed CrossRef
Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–226. PubMed CrossRef
Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105. PubMed CrossRef
Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90. PubMed CrossRef
Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. PubMed CrossRef
Gaspersz R, Nawijn L, Lamers F, et al. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17–25. PubMed CrossRef
May AM, Klonsky ED, Klein DN. Predicting future suicide attempts among depressed suicide ideators: a 10-year longitudinal study. J Psychiatr Res. 2012;46(7):946–952. PubMed CrossRef
Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005;62(11):1249–1257. PubMed CrossRef
Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract. 2004;10(5):296–306. PubMed CrossRef
Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMed CrossRef
Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Focus Am Psychiatr Publ. 2016;14(2):244–265. PubMed CrossRef
Vieta E, Earley WR, Burgess MV, et al. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol. 2019;34(2):76–83. PubMed CrossRef
Yoon S, Jeon SW, Ko Y-H, et al. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2017;37(1):46–53. PubMed CrossRef
Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249–258. PubMed CrossRef
Pignon B, Tezenas du Montcel C, Carton L, et al. The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep. 2017;19(12):103. PubMed CrossRef
de Miranda AS, Ferreira RN, Teixeira AL, et al. Mood Stabilizers: Quetiapine. NeuroPsychopharmacotherapy; 2020:1–23.
Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT_1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303–2312. PubMed CrossRef
Duncan D, Cooke L, Symonds C, et al. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016;6(3):e010861. PubMed CrossRef
Ketter TA, Miller S, Dell’Osso B, et al. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256–273. PubMed CrossRef
Ignácio ZM, Calixto AV, da Silva RH, et al. The use of quetiapine in the treatment of major depressive disorder: evidence from clinical and experimental studies. Neurosci Biobehav Rev. 2018;86:36–50. PubMed CrossRef
Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–276. PubMed CrossRef
Stein DJ, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26(8):614–628. PubMed CrossRef
Endicott J, Svedsäter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301–311. PubMed CrossRef
Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574–586. PubMed CrossRef
Bandelow B, Bauer M, Vieta E, et al. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry. 2014;15(2):155–166. PubMed CrossRef
McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–494. PubMed CrossRef
Li X, Xing B, Yu E, et al. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci. 2013;25(2):157–160. PubMed CrossRef
Li R, Wu R, Chen J, et al. A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder. Psychopharmacol Bull. 2016;46(1):8–23. PubMed
Chen Y-C, Chen C-K, Wang L-J. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. BMC Psychiatry. 2012;12(1):162. PubMed CrossRef
First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders: Patient Edition. Biometrics Research Department, Columbia University: New York, NY; 2005.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. PubMed CrossRef
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. PubMed CrossRef
Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service; 1976.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–571. PubMed CrossRef
Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. PubMed
Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487–495. PubMed CrossRef
Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–173. PubMed CrossRef
Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571–1575. PubMed CrossRef
McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother. 2009;10(18):3061–3075. PubMed CrossRef
Stein MB, Fuetsch M, Müller N, et al. Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry. 2001;58(3):251–256. PubMed CrossRef
Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183–192. PubMed CrossRef
de Graaf R, Bijl RV, Ten Have M, et al. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. J Affect Disord. 2004;82(3):461–467. PubMed CrossRef
Khan A, Detke M, Khan SR, et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211–218. PubMed CrossRef
Maslej MM, Furukawa TA, Cipriani A, et al. Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials. JAMA Psychiatry. 2020;77(6):607–617. Retracted in: JAMA Psychiatry. 2020;77(8):786. PubMed CrossRef
McElroy SL, Weisler RH, Chang W, et al; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–174. PubMed CrossRef
Young AH, McElroy SL, Bauer M, et al; EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150–162. PubMed CrossRef
Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609. PubMed CrossRef
Hirschfeld RM, Weisler RH, Raines SR, et al; BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(3):355–362. PubMed CrossRef
Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat. 2008;4(1):11–21. PubMed CrossRef